Wegovy Prior Authorization Denied? How to Overturn It (2026)

Getting a Wegovy denial letter in the mail is genuinely frustrating — you and your doctor agreed this medication makes sense, and now an insurance plan is saying no.

Here's the good news: a first denial is not a final answer.

Most denials happen for a small set of fixable reasons, and knowing exactly which one applies to you changes everything about how you respond.

In this guide, you'll learn the exact reasons plans deny Wegovy in 2026, the step-by-step appeal ladder you can climb, the single strongest clinical framing that overturns the most denials, and what to do if the appeal doesn't work.

Why Wegovy Prior Authorization Gets Denied (The Real Reasons)

Insurance plans deny Wegovy for a surprisingly short list of reasons.

Once you identify which reason is on your denial letter, you can stop guessing and start building the right response.

Reason 1: The Plan Excludes Weight-Loss Drugs Entirely

This is the most common denial — and the most misunderstood one.

Many employer-sponsored plans and most standard Medicare plans write anti-obesity medications out of the benefit design entirely as a category.

That means the denial has nothing to do with your BMI, your chart, or your doctor's note. The drug simply isn't a covered benefit for weight loss under that plan, full stop.

Here's the deal:

A clinical appeal — the kind where you send more medical records — cannot overturn a benefit-design exclusion. You need a different strategy entirely (more on that in Sections 3 and 4).

Reason 2: BMI or Comorbidity Not Documented

Plans that do cover Wegovy require a qualifying BMI — typically BMI ≥ 30, or BMI ≥ 27 with at least one weight-related condition such as hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.

The catch: the number has to appear in your chart at the time of the prior-authorization request, not just in your doctor's memory.

If your physician's note from the PA visit didn't include a documented BMI or didn't explicitly link your diagnosis to a qualifying comorbidity, the plan's reviewer may have no basis to approve — even if you clearly qualify clinically.

Reason 3: Step Therapy Not Completed (or Not Documented)

Some plans require you to try and fail a cheaper or "preferred" medication before they'll approve Wegovy.

Even if you did try something else years ago, that trial needs to be in your chart with dates, doses, and the reason it didn't work — otherwise the plan treats it as if it never happened.

Reason 4: Off-Label Use Request

Ozempic and Mounjaro are FDA-approved for type 2 diabetes — not weight loss. Wegovy is FDA-approved for weight loss (and cardiovascular risk reduction).

If someone requests Wegovy under a diabetes framing it doesn't match, or requests a diabetes drug for a weight-loss indication, the plan will deny it for off-label use.

Reason 5: Formulary Mismatch

Your plan may cover a GLP-1 — just not Wegovy specifically. A different GLP-1 may be the plan's preferred agent, and Wegovy requires a non-preferred exception.

The 4-Step Appeal Ladder (Start Here)

Federal law gives you the right to appeal a prior-authorization denial. Most plans have a multi-step internal process before you reach outside review.

Here's the thing:

Each step has a purpose. Skipping ahead or sending the same materials twice without new information rarely changes anything. Work the ladder in order.

Step 1: Internal Appeal #1 — Letter of Medical Necessity

This is the first and most important step.

Your prescriber submits a letter of medical necessity that ties your documented medical record directly to each criterion the plan named in the denial letter.

The letter needs to address every named gap — not just restate that the medication is appropriate. If the plan said your BMI wasn't documented, the letter should reference the specific chart date and value. If step therapy wasn't documented, the letter should list the prior drug, the dates, the dose, and why it failed.

For a complete template your doctor can use, see our GLP-1 coverage appeal letter that actually works.

• Reference the exact denial reason by name
• Include the chart date and documented BMI value
• List all qualifying comorbidities with ICD-10 codes
• Document prior therapy attempts with dates and outcomes
• Include diet and lifestyle program participation with dates
• State the FDA-approved indication being requested

Step 2: Peer-to-Peer Review

If the first appeal is denied, your prescriber can request a peer-to-peer review — a direct phone call with the plan's medical director.

This is often where clinical denials get overturned, because a real physician is explaining the case to another real physician rather than a form going through an automated review.

Encourage your prescriber to ask for this call proactively, before waiting for a second denial letter.

Step 3: Internal Appeal #2

If new documentation has become available — a new diagnosis, a completed lifestyle program, updated lab values — a second internal appeal gives you a chance to submit it.

Don't file a second appeal with the same package you already submitted. Something needs to be new.

Step 4: External Independent Review

Once you've exhausted internal appeals, you can request an external review by an independent review organization (IRO) — a neutral third party that is not affiliated with your insurer.

For clinical denials (where the plan says the drug isn't medically necessary for you specifically), external review is often the most powerful step.

For benefit-design exclusions (where the plan says weight-loss drugs aren't covered at all), external review is less likely to change the outcome — the IRO generally can't rewrite a plan's benefit design.

For a deeper look at what plans require before they'll approve coverage in the first place, read our guide to GLP-1 prior authorization: the exact requirements and how to meet them.

The Strongest Indication to Use in Your Appeal

This section is the one most people — and many prescribers — don't know about.

Here's what changes everything:

Wegovy carries an FDA indication to reduce cardiovascular risk in adults with established cardiovascular disease who also have obesity or overweight.

That is not a weight-loss framing. It is a cardiovascular disease treatment framing.

Plans that exclude anti-obesity medications as a category often still cover cardiovascular disease treatments. If a patient has documented cardiovascular disease — coronary artery disease, prior heart attack, prior stroke, peripheral arterial disease — and also has obesity or overweight, Wegovy may be requestable under that cardiovascular indication instead.

This single reframing has unlocked coverage for patients who had been told no multiple times under a weight-loss request.

The Diabetes Angle

If you have type 2 diabetes, the coverage picture changes dramatically.

Semaglutide (as Ozempic) and tirzepatide (as Mounjaro) are covered for type 2 diabetes by nearly every commercial plan, most Medicaid programs, and Medicare Part D.

A prescriber who frames the request around diabetes management — when that diagnosis genuinely applies — is working with a far stronger coverage record than a weight-loss request faces.

This isn't about gaming the system. It's about making sure the request reflects the patient's full clinical picture.

The Comorbidity Tier

For patients at BMI 27–29 who don't qualify on BMI alone, documented comorbidities are the key to the covered tier.

Hypertension, dyslipidemia, obstructive sleep apnea, prediabetes, and cardiovascular disease each count as qualifying conditions under most plan criteria — but only if they appear in the chart with a diagnosis code at the time of the PA request.

If your doctor manages those conditions but hasn't documented them explicitly in the note accompanying the PA, that's a documentation gap — not a clinical one — and it can be fixed.

What to Do If the Appeal Fails

Some denials won't move — especially hard benefit exclusions where the plan simply doesn't cover weight-loss medications as a category.

That is not the end of the road. It's a signal to pivot.

Let's be direct:

If your plan excludes anti-obesity medications entirely, you are not going to win that fight through clinical appeals alone. External review can occasionally push on this, but it is not a reliable path. Your energy is better spent on the alternatives below.

Option 1: Escalate Through HR (Employer Plans)

If your coverage is through an employer, the exclusion of weight-loss drugs is a plan design choice your employer made — often because of cost. You can raise this with HR or a benefits committee. Some employers have added GLP-1 coverage in response to employee requests, especially when the cardiovascular and productivity data is presented alongside the ask.

Option 2: Look at the Open Enrollment Window

If another plan offered through your employer or marketplace covers GLP-1s for weight loss, open enrollment may be your most reliable path to coverage — worth checking every year as plan formularies shift.

Option 3: Reframe the Indication (With Your Doctor)

As discussed in Section 3, the cardiovascular indication or a diabetes framing — when either genuinely applies to your clinical situation — may succeed where a weight-loss request failed. This is a conversation to have with your prescriber.

Our article on what to do when insurance won't cover Wegovy for weight loss walks through each of these pivots in more detail.

Cash-Pay Backup Paths (Prices as of June 2026)

If coverage isn't working right now, cash-pay options have gotten meaningfully more affordable in 2026.

These programs don't require insurance approval. They do have expiration dates and dose limits, so verify current terms before counting on them.

Wegovy Injection

Novo Nordisk's Wegovy Savings Offer brings the cost to $199 per month for the first two fills for new patients (through June 30, 2026), then approximately $349 per month for most doses — or $399 per month for the higher-dose Wegovy HD. The list price without any program runs $1,350–$1,640 per month.

Wegovy Pill (Oral Semaglutide)

The oral version of semaglutide — taken daily as a pill — is available at a self-pay price of $149 per month for the 1.5 mg and 4 mg doses. The $149 price for the 4 mg dose is confirmed through August 31, 2026, after which it rises to approximately $199 per month.

Zepbound (Tirzepatide)

Lilly's LillyDirect self-pay vials start from approximately $299 per month for lower doses. Higher doses cost more — verify current pricing directly through LillyDirect since it changes with dose.

Foundayo (Orforglipron) — New in 2026

Foundayo is the first oral GLP-1 pill of its kind (not an oral version of an existing injectable). FDA-approved April 1, 2026, it's available at $149 per month self-pay, as low as $25 per month with a commercial-insurance savings card, and approximately $50 per month for eligible Medicare Part D members through the GLP-1 Bridge program.

One more thing:

Manufacturer savings cards — including Novo Nordisk's — require commercial insurance and explicitly exclude government plan members (Medicare, Medicaid, Tricare). If a savings card "doesn't work" for you, that exclusion is almost certainly why. The cash self-pay programs above don't have that restriction.

For a full breakdown of every cost path by drug and situation, visit our GLP-1 cost ladder.

Medicare and Medicaid: A Different Rulebook

Standard Medicare has not covered GLP-1 medications for weight loss — only for approved uses like type 2 diabetes or cardiovascular disease.

That is starting to change, but only in a limited way.

The Medicare GLP-1 Bridge (Starts July 1, 2026)

A time-limited Medicare demonstration program begins July 1, 2026 that brings GLP-1 costs to approximately $50 per month after deductible for eligible Part D members.

Covered drugs under the Bridge include injectable Wegovy, Ozempic, Mounjaro, and Zepbound, as well as the Wegovy pill — and Foundayo at approximately $50 per month for eligible members.

The critical caveat: this is a limited, time-bound demonstration — not permanent coverage. Not every plan participates, and not every person qualifies. If you're on Medicare, check with your Part D plan directly to confirm whether you're eligible.

For the full breakdown on what Medicare covers and how the Bridge works, visit our Medicare GLP-1 Bridge guide.

Medicaid

Medicaid covers GLP-1 medications for type 2 diabetes in nearly every state.

Coverage for weight loss is the variable — and it varies significantly by state. As of 2026, thirteen states have confirmed weight-loss GLP-1 coverage, while three states — California, Michigan, and Pennsylvania — have confirmed they are cutting it in 2026.

If you're on Medicaid, your state matters more than any other factor. See our state-by-state Medicaid GLP-1 guide for current coverage status.

Your Next Move

A Wegovy prior-authorization denial is not a closed door — it's a signal that something specific needs to be addressed, whether that's a documentation gap, a framing issue, or a plan design that requires a different strategy entirely.

Start by reading your denial letter word for word, identify which of the six denial reasons applies to you, and then work the appeal ladder in order — beginning with a targeted letter of medical necessity that addresses the exact named gap, not a generic appeal.

If the plan has a hard benefit exclusion, don't spend months fighting a wall — pivot to the cardiovascular indication (if it applies), a cash-pay path, or the Medicare Bridge if you're eligible.

What does your denial letter say was the reason — was it a benefit exclusion, a documentation gap, or something else? Knowing that one detail changes everything about your next step.